Sucampo Pharmaceuticals, Inc. (SCMP) said it obtained approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation, or CIC, and associated symptoms in adults, when response to diet and other non-pharmacological measures are inappropriate.
Ryuji Ueno, chief executive officer of Sucampo, commented, "The approval of AMITIZA in the U.K. is an important step in Sucampo's comprehensive initiative to increase the global reach of AMITIZA. We look forward to expanding the AMITIZA franchise into additional indications, such as opioid induced constipation, and geographic locations so that more patients can access this breakthrough medication."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.